Rodolfo A. Lizárraga-Valadez
Rodolfo A. Lizárraga-Valadez has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Sosa-Peinado
Laboratorio de Fisicoquímica e Ingeniería de Proteínas, Departamento de Bioquímica, Facultad de Medicina
1 shared publication - Francisco Cortés-Benítez
Laboratorio de Síntesis y Aislamiento de Sustancias Bioactivas Departamento de Sistemas Biológicos División de Ciencias Biológicas y de la Salud Universidad Autónoma Metropolitana ‐ Unidad Xochimilco Ciudad de México México
1 shared publication - Martín González-Andrade
Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de Mexico, Ciudad de Mexico 04510, Mexico
1 shared publication - Nathaly Vasquez-Martínez
Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de Mexico, Ciudad de Mexico 04510, Mexico
1 shared publication
Latest Publications
- Open Access
- 12 June 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (7) , 1440-1447
Uncompetitive Allosteric Inhibition of PTP1B by BP-1-102 Reveals a Potential Dual-Target Strategy toward the PTP1B–STAT3 Oncogenic Axis: Biochemical and Computational Evidence
Selective PTP1B inhibitors paradoxically potentiate oncogenic STAT3 signaling by restoring JAK2 activity, underscoring the need for dual-target strategies. Here we report that BP-1-102, an orally bioavailable STAT3 SH2 domain inhibitor, also potently inhibits PTP1B with IC50 values of 5.32 μM (hPTP1B1–400) and 11.7 μM (hPTP1B1–285), with ≥37.7-fold selectivity over TCPTP. Kinetic analysis identified an uncompetitive mechanism, suggesting inhibitor binding to the enzyme–substrate complex at a site distal to the active site. Docking and 500 ns molecular dynamics simulations revealed a dual-anchor binding mode involving the 113–123 loop (Cys121) and the proline-rich C-terminal disordered region, a structural interface absent in TCPTP. Umbrella sampling confirmed favorable passive membrane permeability through a tumor-mimetic bilayer (ΔG = −13.83 kcal/mol). These results propose BP-1-102 as a candidate for dual-function inhibitor of the PTP1B–JAK2–STAT3 oncogenic axis, providing a physicochemical and mechanistic rationale for its further evaluation in tumors where both targets are coactivated.
- 12 June 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (7) , 1440-1447
Open AccessUncompetitive Allosteric Inhibition of PTP1B by BP-1-102 Reveals a Potential Dual-Target Strategy toward the PTP1B–STAT3 Oncogenic Axis: Biochemical and Computational Evidence
Selective PTP1B inhibitors paradoxically potentiate oncogenic STAT3 signaling by restoring JAK2 activity, underscoring the need for dual-target strategies. Here we report that BP-1-102, an orally bioavailable STAT3 SH2 domain inhibitor, also potently inhibits PTP1B with IC50 values of 5.32 μM (hPTP1B1–400) and 11.7 μM (hPTP1B1–285), with ≥37.7-fold selectivity over TCPTP. Kinetic analysis identified an uncompetitive mechanism, suggesting inhibitor binding to the enzyme–substrate complex at a site distal to the active site. Docking and 500 ns molecular dynamics simulations revealed a dual-anchor binding mode involving the 113–123 loop (Cys121) and the proline-rich C-terminal disordered region, a structural interface absent in TCPTP. Umbrella sampling confirmed favorable passive membrane permeability through a tumor-mimetic bilayer (ΔG = −13.83 kcal/mol). These results propose BP-1-102 as a candidate for dual-function inhibitor of the PTP1B–JAK2–STAT3 oncogenic axis, providing a physicochemical and mechanistic rationale for its further evaluation in tumors where both targets are coactivated.